Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results

Xeris Biopharma (NASDAQ:XERS) posted its quarterly earnings results on Thursday. The company reported $0.01 EPS for the quarter, FiscalAI reports. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Q1 net product revenue rose 43% to $82.5M (total revenue $83.1M) and management raised FY revenue guidance to $380M–$390M, lifting the low end of prior guidance.
• RECORLEV nearly doubled to $49.8M on record referrals and new patient starts, and the company completed its commercial expansion (≈80 reps, targets increased to ~12,000), with incremental impact expected in H2.
• Gvoke was flat at $20.8M and underperformed internal expectations due to Medicare policy/plan resets that raised out‑of‑pocket costs and reduced prescription fills; management expects a recovery later in the year.
• The pipeline candidate XP‑8121 is on track to start Phase III later this year, leveraging the company’s XeriSol and device capabilities, with R&D spend planned to increase to support the program.
• Profitability metrics improved—gross margin 87% (+2%), adjusted EBITDA $15.1M, and net income $2.2M—with management reiterating a commitment to positive adjusted EBITDA for 2026 despite higher SG&A and R&D investments.

Xeris Biopharma Trading Up 4.1%

XERS traded up $0.26 on Thursday, hitting $6.63. The company had a trading volume of 5,563,284 shares, compared to its average volume of 1,314,657. The firm has a market cap of $1.14 billion, a P/E ratio of -662.34 and a beta of 0.85. Xeris Biopharma has a 1 year low of $4.30 and a 1 year high of $10.08. The company’s fifty day moving average price is $5.92 and its 200 day moving average price is $6.96. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10.

Insider Activity

In related news, Director James Aloysius Brady sold 10,834 shares of the business’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the sale, the director directly owned 89,166 shares in the company, valued at approximately $493,979.64. The trade was a 10.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $6.23, for a total value of $103,835.41. Following the completion of the transaction, the insider directly owned 1,193,173 shares of the company’s stock, valued at approximately $7,433,467.79. This represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 60,835 shares of company stock worth $367,860. 6.47% of the stock is owned by insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors have recently bought and sold shares of XERS. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma in the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd grew its position in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after acquiring an additional 5,000 shares in the last quarter. Truvestments Capital LLC grew its position in Xeris Biopharma by 96.1% in the 4th quarter. Truvestments Capital LLC now owns 8,118 shares of the company’s stock valued at $64,000 after acquiring an additional 3,979 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in Xeris Biopharma in the 4th quarter valued at about $67,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on XERS. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.